Pre-diagnosis thyroid biomarkers and breast cancer survival: evidence from a European prospective cohort study
Clicks: 4
ID: 318958
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
4 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #333 of 343 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 343 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Despite improved treatments and survival, breast cancer (bc) remains a leading cause of cancer mortality in women. Thyroid dysfunction has been linked to bc risk, but its impact on bc survival is less clear. We investigated associations between pre-diagnosis thyroid-related biomarkers and all-cause and bc-specific survival. Methods A prospective cohort study including 1,513 women with invasive bc from 7 European countries in the European Prospective Investigation into Cancer and Nutrition (EPIC) was conducted. We measured thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and anti-thyroid peroxidase antibodies (Anti-TPO) in samples collected ∼8 years pre-diagnosis. We evaluated associations between these markers and all-cause and bc-specific mortality using Cox proportional hazards models adjusted for relevant covariates. Results After mean follow-up postdiagnosis of 7 years, 223 deaths occurred, including 161 from bc. We observed no overall associations between circulating levels of TSH, thyroid hormones, thyroid autoimmunity, and mortality. However, in stratified analyses, TSH was inversely associated with all-cause (HR1-standard deviation (SD)=0.70; 95%CI = 0.52-0.94) and bc-specific-mortality (HR1-SD=0.61(0.44-0.84) in premenopausal women, while fT4 was associated with all-cause mortality in metastatic bc (HR1-SD=1.67(1.20 to 2.32), and with bc-specific mortality among users of menopausal/contraceptive hormones (HR1-SD=2.76(1.47-5.19). Anti-TPO-positivity was inversely associated with all-cause mortality in women with body mass index <25kg/m2 and in women with oestrogen receptor-negative tumours, separately. Conclusions Thyroid function before diagnosis does not appear to play a major role in bc survival. Although subgroup-specific associations were identified, these findings should be interpreted with caution due to limited statistical power and warrant confirmation in independent populations.
| Reference Key |
openalex_W7166053549
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Carlota Castro‐Espín, Mathilde His, Agnès Fournier, Carine Biessy, Anne‐Sophie Navionis, Azam Majidi, Lene Mellemkjær, A. Nielsen, Thérèse Truong, Matthias B. Schulze, Saverio Caini, Claudia Vener, Gabriela Iannuzzo, Rosario Tumino, Alberto Catalano, Antonio Agudo, Dafina Petrova, Amaia Aizpurua, Marcela Guevara, Konstantinos K. Tsilidis, Alicia K. Heath, Laure Dossus, Sabina Rinaldi |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag195
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.